Wendy Stock to Sialic Acid Binding Ig-like Lectin 2
This is a "connection" page, showing publications Wendy Stock has written about Sialic Acid Binding Ig-like Lectin 2.
Connection Strength
0.353
-
Inotuzumab: from preclinical development to success in B-cell acute lymphoblastic leukemia. Blood Adv. 2019 01 08; 3(1):96-104.
Score: 0.166
-
Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. N Engl J Med. 2016 Aug 25; 375(8):740-53.
Score: 0.139
-
Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22. Clin Cancer Res. 2021 05 15; 27(10):2742-2754.
Score: 0.048